Standout Papers

Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients Wit... 2000 2026 2008 2017 923
  1. Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma (2000)
    Mark R. Middleton, Jean‐Jacques Grob et al. Journal of Clinical Oncology

Immediate Impact

5 by Nobel laureates 26 from Science/Nature 58 standout
Sub-graph 1 of 23

Citing Papers

Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy
2022 Standout
Exploring tissue architecture using spatial transcriptomics
2021 StandoutNature
1 intermediate paper

Works of Paul Statkevich being referenced

Treating cancer with PEG Intron
2002
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
2000 Standout

Author Peers

Author Last Decade Papers Cites
Paul Statkevich 2044 954 965 1586 92 4.7k
E Frei 2219 1167 631 1783 104 6.1k
Philip S. Schein 2387 1190 507 1516 177 6.4k
Bert L. Lum 2307 803 315 1802 83 4.6k
Roscoe F. Morton 4512 1851 1072 1943 97 7.6k
Neeltje Steeghs 2719 1837 583 1610 238 5.1k
Raymond J. Hohl 1513 618 306 2256 138 4.8k
Ferry A.L.M. Eskens 2813 1446 388 2570 159 6.2k
Robert Justice 2481 1657 493 2757 61 6.3k
Jean‐Pierre Armand 3673 2015 453 2592 161 6.8k
A. Hilary Calvert 2996 1064 300 2229 74 5.8k

All Works

Loading papers...

Rankless by CCL
2026